Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
98.93
-1.95 (-1.93%)
May 21, 2026, 11:31 AM EDT - Market open

Protagonist Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-114.71-130.15275.19-78.96-127.39-125.55
Depreciation & Amortization
1.451.280.830.981.030.81
Stock-Based Compensation
46.6945.9737.5529.2924.216.4
Other Adjustments
-4.5-5.64-6.81-2.041.793.79
Change in Receivables
-53.66164.88-155-9.994.24-0.92
Changes in Accounts Payable
5.493.720.84-2.931.22-3.22
Changes in Accrued Expenses
5.64.584.29-5.6-12.7219.1
Changes in Income Taxes Payable
-1.89-2.692.69---
Changes in Unearned Revenue
-18.79-21.0230.57--1.6-12.88
Changes in Other Operating Activities
-4.58-3.26-5.99-0.991.09-5.4
Operating Cash Flow
-116.6457.67184.15-70.24-108.14-107.87
Operating Cash Flow Growth
--68.68%----
Capital Expenditures
-1.26-1.59-1.36-0.61-0.8-1.1
Purchases of Investments
-401.51-546.59-621.7-191.05-214.87-286.59
Proceeds from Sale of Investments
538.74498.84323.57152.4307.14271.83
Investing Cash Flow
135.96-49.33-299.48-39.2691.47-15.86
Issuance of Common Stock
34.823.3426.45171.2519130.11
Repurchase of Common Stock
--0.48-0.6-0.77-0.19-0.19
Net Common Stock Issued (Repurchased)
34.822.8625.85170.4818.81129.92
Other Financing Activities
----0.03-
Financing Cash Flow
34.822.8625.85170.4818.84129.92
Effect of Exchange Rate Changes on Cash and Cash Equivalents
-----0.09-0.13
Net Cash Flow
54.1231.2-89.4860.982.086.07
Free Cash Flow
-117.956.08182.8-70.85-108.93-108.97
Free Cash Flow Growth
--69.32%----
FCF Margin
-159.18%121.87%42.08%-118.08%-409.81%-398.31%
Free Cash Flow Per Share
-1.800.882.81-1.25-2.22-2.35
Levered Free Cash Flow
-128.69-149.13307.05-88.11-139.16-128.24
Unlevered Free Cash Flow
-159.76-178.13280.89-102.81-143.14-128.53
Updated May 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q